Company intelligence / Profile preview

Samsung

Incheon, South Korea

Ownership: Private
Employees: ~3400
Development stage: Other

Overview

Samsung Biologics is one of the world’s largest contract development and manufacturing organizations (CDMOs), specializing in mammalian cell-based biologics. It has secured regulatory approvals for commercial manufacturing and works with 16 of the world’s top 20 pharmaceutical companies.

Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatemRNA-based drugs
Industry: Contract Manufacturing Organization

Partnerships

PfizerGlaxoSmithKlineEli LillyAstraZenecaBristol-Myers SquibbModernaLigaChem (formerly LegoChem Biosciences)Kurma Partners

Beyond the preview

Go deeper on Samsung.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samsung.

Explore the full profile